The aim of this study was to determine the performance of both cefotaxime and ceftazidime 25 containing agars on the specificity and sensitivity for chromosomal plasmid AmpC harboring Escherichia coli compared to ESBL-producing E. coli and E. coli without 27 ESBL, pAmpC or cAmpC hyperproduction. Second, we evaluated the influence of adding 28 cefoxitin to these agars for detection of both chromosomal AmpC-hyperproducing and plasmid 29 AmpC harboring E. coli. 30 Four different homemade screening agars with cefotaxime (1mg/L), ceftazidime (1mg/L), 31 cefotaxime (1mg/L) with cefoxitin (8mg/L), and ceftazidime (1mg/L) with cefoxitin (8mg/L) were 32 compared to each other for the identification of AmpC producing E. coli. A total of 40 isolates 33 with plasmid encoded AmpC β-lactamases, 40 isolates with alterations in the 34 promoter/attenuator region of the AmpC gene leading to hyperproduction of the β-lactamase, 35 40 isolates with ESBL genes and 39 isolates lacking both a AmpC and ESBL genotype were used 36
Over the past decades, the importance of resistant Enterobacteriales increased substantially 51 due to the emergence of various resistance traits that inactivate most β-lactam antibiotics. In 52 Escherichia coli, resistance to 2 nd and 3 rd generation cephalosporins is most frequently due to 53 the occurrence of plasmid-encoded ESBL, as well as both plasmid-encoded (pampC) and 54 chromosomally-encoded (campC) AmpC genes. As the rapid and accurate detection of resistant 55 bacteria is crucial for treatment and control, selective media for detection of extended-56 spectrum β-lactamase-producing Enterobacteriales (ESBL-E) have been developed. A 57 considerable number of studies were published on the performance of ESBL-E (1-5) screening 58 agars. So far, few studies have focused on screening media for AmpC β-lactamase-producing cefotaxime or ceftazidime may result in an AmpC specific screening agar, which could be of 88 additional value to the use of an ESBL-agar with cloxacillin. 89 90 The first aim of this study was to determine the performance of both cefotaxime and 91 ceftazidime containing agars on the specificity and sensitivity for AmpC-producing E. coli 92 compared to ESBL-producing and AmpC/ESBL negative E. coli. Second, we evaluated the 93 influence of adding cefoxitin to these agars for detection of AmpC producing E. coli. hyperproduction based on genotype (referred in this study as "AmpC/ESBL negative"). The ESBL- 103 producing E. coli and AmpC/ESBL negative E. coli isolates were confirmed to lack any known 104 alterations in the promoter/attenuator region of the AmpC gene leading to hyperproduction of 105 the β-lactamase, as reported by Tracz et al (7) . Isolates were recovered at different study sites 106 or from various clinical specimens, and were isolated from humans (n=141) and animals (n=18) (15) (16) (17) (18) (19) (20) . More detailed information on the recovery of the isolates is described in the additional 108 file 1. Additional file 2 shows an overview of all strains. isolates was seen on the ceftazidime agar. 160 The cefotaxime + cefoxitin agar showed growth of 39 (97.5%) pAmpC isolates, 39 (97.5%) 161 cAmpC isolates, 17 (42.5%) ESBL isolates and one (2.6%) AmpC/ESBL negative isolate. The 162 ceftazidime + cefoxitin agar showed growth of 39 (97.5%) pAmpC isolates, 40 (100%) cAmpC 163 isolates, 15 (37.5%) ESBL isolates and none of the AmpC/ESBL negative isolates. In both agars 164 the pAmpC isolate that did not grow was the same and appeared to contain a blaACC gene. The 165 ATCC control E. coli strain did not grow on any of the evaluated agars. Four different screening agars were evaluated on their ability to identify AmpC producing E. coli. 188 Cefotaxime-and ceftazidime containing agar showed similar results in sensitivity and specificity 189 for AmpC detection in the tested panel of E. coli isolates. The addition of cefoxitin increased 190 specificity for AmpC detection, but did not influence sensitivity. 191 Although there are no studies on AmpC selective agars, these results are in line with studies 193 showing that cefoxitin might be a useful screening additive for AmpC production(11-13). 194 Polsfuss et al analyzed the use of cefoxitin disc diffusion compared to cefotetan for different 195 Enterobacteriales (13) showed a sensitivity of 97,4% and a specificity of 78,7%. The use of cefotetan, another type of 205 cephamycin, was tested as well, but although this method showed a better specificity (99,3%), 206 sensitivity was much lower (52,6%). Clearly, there are more limitations in the present study. First, this study is an analytical 225 exploration of sensitivity and specificity based upon retrospectively selected strains. Although 226 the panel of strains was selected on genotype, all strains were obtained from clinical or study 227 collections in which different culture screening criteria were used. We tried to minimize 228 selection bias based upon our screening criteria, but the distribution of our collection may not 229 be completely comparable to a clinical setting. The use of mainly CMY-group pAmpC isolates 230 may have led to overestimation of sensitivity in some degree. However, the CMY-group seems 231 to be the predominant pampC gene in clinical settings, and the cefoxitin containing agars may 232 be therefor applicable in these setting for e.g. screening of AmpC rectal carriage.
We remodeled specificity for the cefotaxime 1mg/L + cefoxitin 8mg/L and ceftazidime 1mg/L + 235 cefoxitin 8mg/L agar, as the number of ESBL isolates seems to influence agar specificity. We 236 expect that in a low endemic setting of ESBL specificity of both cefoxitin containing agars will 237 increase. In the Netherlands prevalence of ESBL rectal carriage has been found to range from 238 5% in a teaching hospital in the South of the Netherlands (25) Our study was performed using strains cultured in semi-selective pre-enrichment broth. This 245 pre-enrichment step was included to mimic our laboratory algorithm for screening of 246 multiresistant Enterobacterales in rectal samples. Former studies on the screening of third 247 generation cephalosporin resistance have shown that a pre-enrichment strategy results in 248 higher yield compared to direct plating (28) (29) (30) . We assume that that the use of a pre-249 enrichment strategy in clinical setting will result in a similar detection range, though inoculum 250 of the original sample may differ. A limit of detection is difficult to obtain, as it is not well known 251 which load in clinical samples is comparable to an in vitro setting. Our strategy using the 252 combination of pre-enrichment and selective screening agars was applied in a prevalence study 253 on AmpC in the Amphia hospital (16). Yield of AmpC E. coli was comparable to other Dutch 254 prevalence studies (31,32). However, a more elaborate evaluation of clinical samples is needed In this study the use of screening agars was only assessed on E. coli, as this is one of the most 258 prevalent Enterobacteriales with acquired β-lactamase genes. We expect the agar to be useful 259 for other AmpC producing Enterobacteriales, however sensitivity and specificity for other 260 species may differ. For example, K. pneumoniae without pAmpCs can be cefoxitin-resistant due 261 to loss of porin expression (33). Furthermore, not all existing β-lactamase groups were included. 
